论文部分内容阅读
目的观察人脐带血干细胞治疗失代偿期酒精性肝硬化患者的安全性及对肝功能的改善作用。方法选择失代偿期酒精性肝硬化患者80例,随机分为治疗组40例和对照组40例。对照组行护肝治疗,治疗组在此基础上经股动脉插管至肝固有动脉,注入脐带血单个核细胞1~5×107治疗。结果治疗后8 w,治疗组和对照组血清ALB水平分别为(32.3±8.3)g/L和(24.6±7.7)g/L,PTA分别为(74.0±12.4)%和(58.3±12.3)%,差异有显著性(P<0.05);GGT水平分别为(249.3±17.5)U/L和(358.3±16.5)U/L,ALP水平分别为(370.3±16.5)U/L和(490.3±17.5)U/L,MCV水平分别为(89.5±5.4)fl和(102.8±4.6)fl,淋巴细胞计数分别为(2.8±0.5)和(4.9±0.4)×10~9/L(P<0.05)。结论人脐带血干细胞治疗失代偿期酒精性肝硬化患者可以改善肝脏的合成功能,安全性好。
Objective To observe the safety of human umbilical cord blood stem cells in patients with decompensated alcoholic liver cirrhosis and its effect on improving liver function. Methods Eighty patients with decompensated alcoholic cirrhosis were randomly divided into treatment group (40 cases) and control group (40 cases). The control group received treatment of liver protection. On the basis of this, the treatment group was intubated via the femoral artery to the hepatic artery, and the umbilical cord blood mononuclear cells (1 ~ 5 × 107) were injected into the treatment group. Results Serum ALB levels of the treated group and the control group were (32.3 ± 8.3) g / L and (24.6 ± 7.7) g / L, respectively, and PTA were 74.0 ± 12.4% and 58.3 ± 12.3% , The difference was significant (P <0.05). The levels of GGT were (249.3 ± 17.5) U / L and (358.3 ± 16.5) U / L respectively, and the ALP levels were (370.3 ± 16.5) U / L and ), And the levels of U / L and MCV were (89.5 ± 5.4) fl and (102.8 ± 4.6) fl respectively, and the lymphocyte counts were (2.8 ± 0.5) and (4.9 ± 0.4) × 10-9 / . Conclusion Human umbilical cord blood stem cells in patients with decompensated alcoholic liver cirrhosis can improve the synthesis of liver function, safety.